---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-003573"
form_type: "8-K"
ticker: "SPRB"
cik: "0001683553"
company_name: "SPRUCE BIOSCIENCES, INC."
filed_at: "2022-03-14T23:59:59+00:00"
generated_at: "2026-06-26T23:15:30.705529+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Spruce Biosciences reports Q4/FY2021 net loss of $9.2M/$42.3M; cash $121.4M

## Summary
- Cash, cash equivalents and investments of $121.4M as of Dec 31, 2021; expected to fund operations into Q2 2024.
- R&D expenses for FY2021: $30.7M, up from $23.9M in 2020; net loss widened to $42.3M from $29.5M.
- Appointed Will Charlton, M.D., M.A.S., as Chief Medical Officer in March 2022; he previously served at 89bio.
- Topline safety data from Cohort 1 of Phase 2 pediatric classic CAH study expected by 1H 2023; PCOS Phase 2 topline also by 1H 2023.
- CAHmelia-203 (adult classic CAH, poor disease control) topline by 2H 2023; CAHmelia-204 (good disease control) by 2H 2024.

## SEC filing metadata
- accession: 0000950170-22-003573
- form_type: 8-K
- ticker: SPRB
- cik: 0001683553
- company_name: SPRUCE BIOSCIENCES, INC.
- filed_at: 2022-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1683553/000095017022003573/0000950170-22-003573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1683553/000095017022003573/sprb-20220314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-003573
- JSON: https://secwatch.observer/filing/0000950170-22-003573.json
- Plain text: https://secwatch.observer/filing/0000950170-22-003573.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.